Optimizing Intradermal Administration of Cryopreserved Plasmodium falciparum Sporozoites in Controlled Human Malaria Infection

Kirsten E. Lyke,* Matthew B. Laurens, Kathy Strauss, Matthew Adams, Peter F. Billingsley, Eric James, Anita Manoj, Sumana Chakravarty, Christopher V. Plowe, Ming Lin Li, Adam Ruben, Robert Edelman, Michael Green, Tina J. Dube, B. Kim Lee Sim, and Stephen L. Hoffman

Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland; Howard Hughes Medical Institute, University of Maryland School of Medicine, Baltimore, Maryland; Sanaria Inc., Rockville, Maryland; Protein Potential LLC, Rockville, Maryland; Centers for Disease Control and Prevention, Atlanta, Georgia; The EMMES Corporation, Rockville, Maryland

Abstract. Controlled human malaria infection (CHMI) is a powerful tool to evaluate malaria vaccine and prophylactic drug efficacy. Until recently CHMI was only carried out by the bite of infected mosquitoes. A parenteral method of CHMI would standardize Plasmodium falciparum sporozoite (PISPZ) administration, eliminate the need for expensive challenge facility infrastructure, and allow for use of many P. falciparum strains. Recently, intradermal (ID) injection of aseptic, purified, cryopreserved PISPZ was shown to induce P. falciparum malaria; however, 100% infection rates were not achieved by ID injection. To optimize ID PISPZ dosing so as to achieve 100% infection, 30 adults aged 18–45 years were randomized to one of six groups composed of five volunteers each. The parameters of dose (1 × 104 versus 5 × 104 PISPZ total dose per volunteer), number of injections (two versus eight), and aliquot volume per ID injection (10 μL versus 50 μL) were studied. Three groups attained 100% infection: 1 × 104 PISPZ in 50 μL/2 doses, 1 × 104 PISPZ in 10 μL/2 doses, and 5 × 104 PISPZ in 10 μL/8 doses. The group that received 5 × 104 PISPZ total dose in eight 10 μL injections had a 100% infection rate and the shortest prepatent period (mean of 12.7 days), approaching the prepatent period for the current CHMI standard of five infected mosquitoes.

INTRODUCTION

Controlled human malaria infection (CHMI) studies have been used as a powerful tool to evaluate malaria vaccine and prophylactic drug efficacy. Until recently CHMI was only carried out by the bite of infected mosquitoes. A parenteral method of CHMI would standardize Plasmodium falciparum sporozoite (PISPZ) administration, eliminate the need for expensive challenge facility infrastructure, and allow for use of many P. falciparum strains. Recently, intradermal (ID) injection of aseptic, purified, cryopreserved PISPZ was shown to induce P. falciparum malaria; however, 100% infection rates were not achieved by ID injection. To optimize ID PISPZ dosing so as to achieve 100% infection, 30 adults aged 18–45 years were randomized to one of six groups composed of five volunteers each. The parameters of dose (1 × 104 versus 5 × 104 PISPZ total dose per volunteer), number of injections (two versus eight), and aliquot volume per ID injection (10 μL versus 50 μL) were studied. Three groups attained 100% infection: 1 × 104 PISPZ in 50 μL/2 doses, 1 × 104 PISPZ in 10 μL/2 doses, and 5 × 104 PISPZ in 10 μL/8 doses. The group that received 5 × 104 PISPZ total dose in eight 10 μL injections had a 100% infection rate and the shortest prepatent period (mean of 12.7 days), approaching the prepatent period for the current CHMI standard of five infected mosquitoes.

*Address correspondence to Kirsten E. Lyke, Center for Vaccine Development, University of Maryland School of Medicine, HSF I, Room 480, Baltimore, MD 21201. E-mail: klyke@medicine.umaryland.edu

The prepatent periods of the three groups in Nijmegen were 13.0, 12.7, and 13.0 days, respectively, and 15.4 and 13.5 for the two groups in Tanzania. Thus in none of the five groups in these two studies did all research subjects become infected, and in none was the prepatent period as determined by microscopy equivalent to the 10.5–12 days typical of CHMI by five mosquito bites.

The results of these two ID CHMI studies posed several questions regarding the administration of PISPZ Challenge. Were too few PISPZ administered? Was aliquot volume too great? Would an increase in number of injections improve efforts to mimic the mechanics of mosquito biting, which involve repetitive probing and injection of microaliquots of PISPZ while biting? The anatomic location of PISPZ injection or the modalities of delivery, such as intramuscular (IM),
intravenous (IV), or a multi-needle microdose injectable device may also be important variables. Based on a design that manipulated three parameters (dose, injection number, and volume), coupled with an assessment of the kinetics and quantification of parasitemia by polymerase chain reaction (PCR), the result of ID administration of PISPZ was further evaluated.

METHODS

Objectives. This study was designed as a dose-ranging, randomized, prospective Phase I cohort study, assessing whether ID administration of cryopreserved PISPZ of the NF54 isolate of P. falciparum (PISPZ Challenge) results in prepatent periods and infection rates similar to those obtained via the bites of mosquitoes. The main objectives were to determine safety and tolerability of parenterally administered CHMI and to discern the optimal dose required to achieve 100% infection in adult subjects. The parameters of 1) dose, 2) number of injections, and 3) aliquot volume were studied.

Study population and design. The clinical study was conducted at the Center for Vaccine Development, at the University of Maryland School of Medicine (UMB) in Baltimore, MD. Thirty malaria-naive adults aged 18–45 years were randomized into one of six groups to receive a total dose of $1 \times 10^4$ (four groups) or $5 \times 10^4$ PISPZ (two groups) of PISPZ Challenge. The total dose was split into either two or eight PISPZ injections administered parenterally via ID injection in either 10 μL (two groups of $1 \times 10^4$ and two groups of $5 \times 10^4$ PISPZ) or 50 μL aliquots (two groups of $1 \times 10^4$ PISPZ) during a single administration session with a total of five subjects per group (Table 1). The lower limit of injectate by needle and syringe is currently $\sim$5–10 μL. As 50-μL injections in two divided doses did not achieve 100% infection, this study was weighted toward an injectate volume of 10 μL. Although increasing the volume of injectate above 50 μL would likely contribute to tissue destruction, it might also lead to sporozoites being trapped within the injectate and unable to be distributed systemically. We postulated the combination of multiple injections and microaliquots of sporozoites might simultaneously enhance tissue destruction while enabling sporozoite penetration into the capillary system allowing for hepatic delivery. An upper limit of eight injections balanced the need to increase injection number while preserving practicality in a clinical trial setting. Participants were randomized by an online allocation sequence generated by the EMMES Corporation (Rockville, MD). Study personnel were blinded to group assignment. Participants were previously screened for good health, including laboratory testing for hepatitis B and C, human immunodeficiency virus, and for pregnancy testing in females of childbearing potential. Baseline complete blood counts, creatinine, glucose, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) were screened and only volunteers with normal values were enrolled. In addition, volunteers with significant cardiovascular risk were excluded (i.e., > 10%, 5-year risk), including evaluation by gender and age for systolic blood pressure (mmHg), smoking status (current versus past or never), body mass index (kg/m²), reported diabetes status, and current treatment of raised blood pressure. A 12-lead electrocardiogram (ECG) was performed and read by a staff cardiologist. Exclusion criteria included known history of malaria infection, long-term residence (> 5 years) in a malaria-endemic area, travel to a malaria-endemic area within the previous 6 months, the presence of hemoglobin S by electrophoresis, and splenectomy.

Dosage, preparation, and administration of study product. The investigational PISPZ Challenge product was cryopreserved, in liquid nitrogen vapor phase at −150 to −196°C, as a suspension of aseptic, purified, replication-intact PISPZ formulated in cryoprotectant. The challenge product was administered ID to the deltoid area of the upper arm within 30 minutes of reconstitution by a study nurse unblinded to the number and volume of assigned injections. After randomization to two or eight injections, half were administered in the right arm and half to the left arm, separated by a width of approximately 1 cm when eight injections were given.

Post-administration assessment. Participants were monitored for 30 minutes after ID CHMI and asked to maintain symptom diaries until Day 7. They were evaluated in clinic on Days 5–7 and admitted to an in-patient ward on Day 8 before the expected time of blood stage parasitemia. Daily histories, vital signs, targeted physical examinations, blood smears, and real-time quantitative PCR (qPCR) assays were performed. Asymptomatic individuals were provided with cell phones, allowed to leave the ward during the day, and return in the evenings for evaluation. Symptomatic or parasitic individuals remained on the ward under clinical supervision. Inpatient analysis occurred from Days 8 to 18 or until documentation of parasitemia and receipt of 1,500 mg chloroquine (CQ) base as standard first-line therapy over 48 hours (600 mg base/1,000 mg salt at time 0 followed by 300 mg oral base/500 mg salt at hours 6, 24, and 48) and two negative blood smears ≥ 12 hours apart. A third negative smear, ≥ 12 hours after the previous two negative smears, was documented as an outpatient to affirm malaria cure. As part of a sub-study to evaluate the kinetics of CQ single-dose therapy, CQ and its highly active metabolite, desethylchloroquine (DCQ), levels in blood and urine were measured in a subset of parasiticemic volunteers on Days 0, 2, 7, 14, 21, and 28 post-malaria diagnosis. The technique for detecting CQ and DCQ has been validated in blood and urine and was performed at the Centers for Disease Control.

| PISPZ Challenge group | Dose of PISPZ | Aliquot volume (μL) | PISPZ/μL injection | Number of injections | Number of Subjects | Age and range | Gender (no. of female) |
|-----------------------|--------------|---------------------|--------------------|---------------------|-------------------|--------------|----------------------|
| A: Medium dose, medium aliquot volume* | 10,000 | 50 | 100 | 2 | 5 | 35.6 (30–43) | 3/5 |
| B: Medium dose, medium aliquot volume | 10,000 | 50 | 25 | 8 | 5 | 38.2 (28–44) | 0/5 |
| C: Medium dose, low aliquot volume | 10,000 | 10 | 500 | 2 | 5 | 36.6 (21–44) | 0/5 |
| D: Medium dose, low aliquot volume | 10,000 | 10 | 125 | 8 | 5 | 31.6 (22–44) | 1/5 |
| E: High dose, low aliquot volume | 50,000 | 10 | 2,500 | 2 | 5 | 29.2 (24–33) | 2/5 |
| F: High dose, low aliquot volume | 50,000 | 10 | 625 | 8 | 5 | 27.8 (24–32) | 5/5 |

PISPZ = Plasmodium falciparum sporozoite; RUNMC = Radboud University Nijmegen Medical Center.

* Group A represents a bridging or reference arm to a previous study performed at RUNMC.
for the presence of blood stage parasites using techniques post-CHMI, daily blood smears were performed to monitor symptoms were considered unsolicited until Day 28. Serious nate confounding variables (Table 3). Any other signs or (NF54) and cultured in the same laboratory facility to elimi-
P. falciparum mosquitoes infected with the same strain of
ditional CHMI using aseptically reared
was made assessing historical results from our site with a tra-
unteer follow-up or until malaria diagnosis. A comparison
CHMI (Table 3) and continued for the duration of the vol-
related to the malaria challenge and before malaria para-
sitemia were recorded until Day 7 post-CHMI (Table 2) and
those related to blood stage malaria began on Day 8 post-
challenged and evaluated until Day 14 post-CHMI. Local reactions that persisted beyond Day 2 were recorded as adverse events based on previous site experience that erythema, pruritus, and induration are normal responses to mosquito bites within two days of exposure. Solicited systemic symptoms related to the malaria challenge and before malaria parasitemia were recorded until Day 7 post-CHMI (Table 2) and those related to blood stage malaria began on Day 8 post-

Assessment of safety and tolerability. All adverse events were graded for 1) severity (mild, moderate, severe, or life threatening) and 2) relatedness (associated or not associated to the study product). Specific severity scales were provided for fever (mild, > 99.5–100.4°F; moderate, > 100.4–102.2°F; and severe, > 102.2°F), and erythema (mild, 2.5–5 cm; moderate, 5.1–10 cm; and severe, > 10 cm). The local injection site was assessed and general solicited symptoms or signs evaluated until Day 14 post-CHMI. Local reactions that persisted beyond Day 2 were recorded as adverse events based on previous site experience that erythema, pruritus, and induration are normal responses to mosquito bites within two days of exposure. Solicited systemic symptoms related to the malaria challenge and before malaria parasitemia were recorded until Day 7 post-CHMI (Table 2) and those related to blood stage malaria began on Day 8 post-

Malaria diagnostics. Blood smears. Beginning on Day 6 post-CHMI, daily blood smears were performed to monitor for the presence of blood stage parasites using techniques previously described.10,11 If participants developed signs or symptoms of malaria, blood smear interval preparation decreased to every 8–12 hours until a diagnosis was established. Two trained investigators, blinded to randomization results, examined approximately 0.5 μL of blood using the 100× oil immersion lens of calibrated microscopes. This was doubled to approximately 1.0 μL for symptomatic individuals. Parasites were quantified per microliters. For positive smears, or if questions or discrepancies arose, an expert reader verified positivity and quantified parasite burden. The minimum criterion for acceptance of a positive smear was identification of two unquestionable P. falciparum parasites. All therapeutic decisions were based on positive blood smear results.

Real-time quantitative DNA polymerase chain reaction. qPCR was performed on 0.5 mL of venous blood collected contemporaneously with blood smears using published methods with minor modifications.12 Samples were blinded and assays were run daily. Deoxyribonucleic acid (DNA) extraction was performed with a QIAamp DNA Mini kit (Qiagen, Hilden, Germany) modified to accommodate 0.5 mL whole blood. Extraction efficiency was verified by the addition and subsequent qPCR analysis of an Extraction Control with a proprietary probe and primers (DNA Extraction Control 560; Bioline, Taunton, MA).PCR primers were based on the published sequence of the highly conserved,13 stage-specific14 P. falciparum 18S ribosomal RNA gene. Primer sequences corresponded to the sequence of the NF54 strain and were as follows: Forward— 5′- GTA ATT GGA ATG ATA GGA ATT TAC AAG GT -3′, Reverse— 5′- TCA ACT ACG AAC GTT TTA ACT GCA AC -3′, and Probe— 5′-FAM GAA CGG GAG GTTA AAC AA MGB-3′. Each sample was run in duplicate along with “no template controls” and against standards at the following P. falciparum concentrations: 600,000; 200,000; 60,000; 20,000; 6,000; 2,000; 600; 200; 60; and 20 parasites/mL diluted in human whole blood. DNA amplification was done as previously described,10,11 but with the preincubation step extended to 15 minutes, on a Applied Biosystems 7300 Real Time PCR System (Foster City, CA). Data were analyzed using the Applied Biosystems 7300 Absolute Quantification Software and were compared with blood smear results.

Antibody assays. Plasmodium falciparum antibodies to circumsporozoite protein (CSP), merozoite surface protein 1 (MSP1), and erythrocyte-binding antigen-175 (EBA-175) by enzyme-linked immunosorbent assay (ELISA), and to sporozoites by the immunofluorescence assay (IFA) were assessed in sera as previously described15 on the day of injection of PfSPZ Challenge and 28 days later. Antibodies against P. falciparum Exported Protein 1 (PiEXP1) were assessed in ELISAs against recombinant PiEXP1 (rPiEXP1) expressed

| Table 2 |
| --- |
| Maximum intensity of solicited signs and symptoms during post-CHMI after receiving Plasmodium falciparum sporozoites by ID injection or by traditional mosquito (first 48 hours of local reactogenicity discounted due to expected reactions associated with mosquito bites) |
| **None** | **Mild** | **Moderate** | **Severe** |
| **Systemic (Day 0–7)** | | | |
| Oral temperature | 30 (100.0) | 0 | 0 | 0 |
| Malaise | 19 (63.3) | 9 (30.0) | 2 (6.7) | 0 |
| Nausea | 27 (90.0) | 2 (6.7) | 1 (3.3) | 0 |
| Myalgia | 21 (70.0) | 4 (13.3) | 5 (16.7) | 0 |
| Headache | 22 (73.3) | 4 (13.3) | 4 (13.3) | 0 |
| Chills | 27 (90.0) | 3 (10.0) | 0 | 0 |
| Vomiting | 29 (96.7) | 1 (3.3) | 0 | 0 |
| **Local (Day 2–14)** | | | |
| Pain | 24 (80.0) | 6 (20.0) | 0 | 0 |
| Tenderness | 26 (86.7) | 3 (10.0) | 1 (3.3) | 0 |
| Erythema | 28 (93.3) | 1 (3.3) | 1 (3.3) | 0 |
| Induration | 30 (100.0) | 0 | 0 | 0 |
| Any local | 22 (73.3) | 6 (20.0) | 2 (6.7) | 0 |
| Any other symptoms | 14 (46.7) | 8 (26.7) | 8 (26.7) | 0 |
| **Post-ID CHMI (N = 30)** | | | |
| None | 22 (88.0) | 3 (12.0) | 0 | 0 |
| Mild | 18 (72.0) | 5 (20.0) | 2 (8.0) | 0 |
| Moderate | 23 (92.0) | 2 (8.0) | 0 | 0 |
| Severe | 25 (100.0) | 0 | 0 | 0 |
| **Post-traditional CHMI (days 2–7) (N = 25)** | | | |
| None | 22 (88.0) | 3 (12.0) | 0 | 0 |
| Mild | 18 (72.0) | 5 (20.0) | 2 (8.0) | 0 |
| Moderate | 23 (92.0) | 2 (8.0) | 0 | 0 |
| Severe | 25 (100.0) | 0 | 0 | 0 |

CHMI = controlled human malaria infection; ID = intradermal.
| Symptoms                        | ID CHMI (all groups) | Traditional challenge | p-value ID vs. traditional |
|--------------------------------|----------------------|-----------------------|---------------------------|
| Total                           | 10 (100.0)           | 25 (100.0)            | NS                        |
| Oral temperature                | 6 (60.0)             | 11 (44.0)             | NS                        |
| Malaise                         | 8 (80.0)             | 20 (80.0)             | NS                        |
| Headache                        | 8 (80.0)             | 18 (72.0)             | NS                        |
| Vomiting                        | 3 (30.0)             | 11 (44.0)             | NS                        |
| Abdominal pain                  | 7 (70.0)             | 11 (44.0)             | NS                        |
| Diarrhea                        | 7 (70.0)             | 23 (92.0)             | NS                        |
| Dizziness                       | 3 (30.0)             | 9 (36.0)              | NS                        |
| Arthralgia                      | 2 (20.0)             | 9 (36.0)              | NS                        |
| Shortness of breath             | 6 (60.0)             | 22 (88.0)             | NS                        |
| Change in exercise              | 5 (50.0)             | 20 (80.0)             | NS                        |
| Palpitations                    | ND                   | ND                    | ND                        |

CHMI = controlled human malaria infection; ID = intradermal; PfSPZ = Plasmodium falciparum sporozoite. Bold values represent those calculations that reached statistical significance.

*p-value determined by Mantel–Haenszel Chi2 analysis (no symptoms vs. symptoms) or Fishers exact (2 tailed) as appropriate between ID CHMI (all groups) and traditional CHMI.
Subject participation began after the diagnosis of peripheral parasitemia by microscopy. Noncompartmental CQ kinetics analysis was used to estimate the slope of the elimination phase, elimination half-life, maximum concentration, time of maximum concentration, and area under the curve. All pharmacokinetic (PK) parameters, with the exception of area under the concentration–time curve from time zero to final sample (AUC_{last}), were estimated with respect to the fourth dose of CQ. Samples with concentrations below the lower limit of quantification (LLQ) were not included in the PK parameter estimation. Subjects with fewer than three sample concentrations above the LLQ, or with an $R^2$ (square of the correlation coefficient) value for elimination phase samples below 0.8, were not included in the analysis. In CQ and DCQ concentration summaries by subject and time point, concentrations below the LLQ were imputed as 0 ng/mL. Elimination half-life was estimated from the slope of the elimination phase, $\lambda_e$. The AUC_{last} was calculated from the first dose to the last sample above the LLQ. The analysis variables consisted of baseline variables, safety variables, efficacy data, and laboratory data. Hours of collected samples and administered doses are calculated from the time of the first dose. PK parameter estimation and statistical analysis were performed in WinNonlin version 6.3 (Certara, Princeton, NJ).

Statistics. The study was designed as a proof-of-concept and was not powered for statistically significant comparisons between groups. Efficacy analysis in this study refers to the efficiency at which 100% infectivity is conferred by each son between groups. Efficacy analysis in this study refers and was not powered for statistically significant comparison. Of the 29 volunteers who completed follow-up through Day 28 post-CHMI, 23 (79.3%) developed patent malaria (Table 4). Two volunteers missed a follow-up day immediately before their malaria diagnosis and their results are removed from group analysis (Volunteer M11UMD012, Group C; and M11UMD060, Group F). Three of the groups (A, C, and F) demonstrated 100% infectivity, which would be expected of the traditional 5-mosquito CHMI. Notably, Groups B and D, which both had a total of eight injections, did not experience higher infectivity nor did the concentration of PfSPZ/mL appear associated with higher infectivity (Tables 1 and 4). In addition, the number of PfSPZ injected (1 × 10^4 versus 5 × 10^4) did not play a role in the resulting quantification of parasitemia at the first positive blood smear (14.8 versus 10.1 parasites/μL [range 2–134], $P = 0.17$). These values were comparable to those from prior CHMI studies conducted at our trial site (geometric mean [GM] of 15.7 [range 4–70 parasites/μL]).

Parasitemia by qPCR was detected in all 23 volunteers who developed smear-positive malaria. Combined data from the 23 participants who developed malaria demonstrated that qPCR detected patency with a GM of 60.5 hours before microscopy (95% confidence interval = 46.4–74.6). However, the kinetics of the malaria infection for ID CHMI appeared different from that observed with CHMI by mosquito bite (traditional CHMI). The prepatent period from ID CHMI to first detectable qPCR was 256.8 hours (10.7 days) as compared with 206.4 hours (8.6 days) by traditional CHMI ($P < 0.001$). This delay in detectable parasites was mirrored in the prepatent period for blood smear detection. A mean prepatent period of 13.5 days (range 12–16) by ID CHMI was detected as compared with a prepatent period of 10.9 days by traditional CHMI ($P < 0.001$). The first detectable qPCR value, however, was not significantly different between ID CHMI and the traditional CHMI (161 versus 193 GM parasites/mL, $P = 0.40$). Parasitemia detection by qPCR was performed daily for diagnostic evaluation compared with more frequent evaluation for kinetic analysis, February 2012 by ID administration of 1 × 10^4 or 5 × 10^4 PfSPZ in 10 or 50 μL aliquots divided into two or eight injections on the same day (Table 1). The safety, tolerability, and efficacy of the inoculation regimens were evaluated. One volunteer was withdrawn post-CHMI due to a work schedule conflict and early termination anti-malaria therapy was provided (Group A). All volunteers completed four weekly safety follow-ups after treatment of malaria or, terminal treatment in the case of volunteers without parasitemia by Day 28 post-CHMI.

Table 4: Results and characteristics of malaria stratified by group

| Study group | Patent volunteers (n) | Prepatent period (days; range)² | Smear parasite density (μL⁻¹)³ | Time (hours) to first PCR (para/μL)² | First PCR positive (para/μL)³ | PCR (para/μL) at patency⁴ |
|-------------|-----------------------|---------------------------------|-----------------------------|-----------------------------------|-----------------------------|--------------------------|
| A: 1 × 10⁴ PfSPZ 2 × 50 μL | 4/4† | 14.5 (13–16) | 14.7 (4–99) | 286.6 (11.9) | 0.156 | 18.3 |
| B: 1 × 10⁴ PfSPZ 8 × 50 μL | 3/5 | 14.0 (14) | 46.3 (25–78) | 258.6 (10.8) | 0.549 | 64.4 |
| C: 1 × 10⁴ PfSPZ 2 × 10 μL | 5/5 | 13.5 (13–14) | 8.1 (2–134) | 259.6 (10.8) | 0.210 | 17.8 |
| D: 1 × 10⁴ PfSPZ 8 × 10 μL | 2/5 | 13.0 (13) | 10.5 (10–11) | 201 (8.4) | 0.050 | 17.2 |
| E: 5 × 10³ PfSPZ 2 × 10 μL | 4/5 | 13.2 (12–15) | 10.2 (5–15) | 239.7 (10.0) | 0.161 | 24.8 |
| F: 5 × 10³ PfSPZ 8 × 10 μL | 5/5 | 12.7 (12–14) | 21.4 (6–46) | 247.6 (10.3) | 0.154 | 25.6 |
| Combined groups | 23/29 | 13.5 (12–16) | 15.0 (2–134) | 256.8 (10.7) | 0.161 (0.015–6.16) | 24.5 (6.8–105) |

CHMI = controlled human malaria infection; PCR = polymerase chain reaction; PfSPZ = Plasmodium falciparum sporozoite.

* Blood smear, time, and PCR quantity expressed as geometric mean PCR parasite density. Prepatent period is expressed as mean.
† Denominator reflects withdrawal of volunteer after CHMI (data from two volunteers removed due to missing interval sample).
which limits our interpretation. However, using the method described by Roestenberg and others and accounting for time in hours, the GM parasite multiplication rate was 9.0 by ID CHMI compared with 13.3 in infectivity controls in a traditional five-mosquito CHMI (unpublished data derived from previous studies conducted at UMB using mosquitoes infected with the 3D7 clone of NF54 strain *P. falciparum*). These minor differences may be of little clinical relevance. By convention, all participants with fewer than four qPCR positive measurements (*N* = 8), were excluded from multiplication rate analysis for a total of 13 evaluable participants. No participants displayed a negative slope. Two volunteers were excluded due to a missing interval sample. The number of parasites detected in the first qPCR cycle of ID CHMI was not significantly different from that detected in the traditional CHMI (85 versus 109 GM parasites/mL, *P* = 0.53).

**Post-administration safety assessment.** Systemic events attributable to the administration of PfSPZ Challenge were ascertained among all subjects through Day 7 post-CHMI (Table 2). Local reactogenicity events from the time of administration were assessed through Day 14. During Days 8–18 post-CHMI through the inpatient stay, systemic reactogenicity events that were expected due to the malaria event were also assessed (Table 3). Safety laboratories were drawn on each day of treatment and subsequent weekly follow-up visits (Days 22, 28, 35, and 42). Five subjects (one in Group B, three in Group D, and one in Group E), who did not develop malaria, were assessed for systemic reactogenicity after inpatient discharge through Day 28 post-CHMI and developed no symptoms with the exception of an unrelated Grade 1 headache. No severe solicited symptoms or signs were noted in volunteers after ID CHMI. Moderate solicited local or systemic events were reported in eight individuals (26.7%) and included five instances of myalgia and four headaches. Mild to moderate reactogenicities were reported most commonly as erythema and injection site tenderness, occurring in a minority of participants. This compared favorably to tabulated signs and symptoms elicited by PfSPZ, delivered by the bite of three aseptic mosquitoes, produced by Sanaria under current Good Manufacturing Practice guidelines. These minor differences may be of little clinical relevance. By convention, all participants with fewer than four qPCR positive measurements (*N* = 8), were excluded from multiplication rate analysis for a total of 13 evaluable participants. No participants displayed a negative slope. Two volunteers were excluded due to a missing interval sample. The number of parasites detected in the first qPCR cycle of ID CHMI was not significantly different from that detected in the traditional CHMI (85 versus 109 GM parasites/mL, *P* = 0.53).

**Antibody results.** Antibodies to PfCSP (expressed in sporozoite and early liver stages), PfEXP1 (expressed in early, mid, and late liver, and asexual erythrocytic stages), and PfMSP1 and PfEBA-175 (expressed in late liver and asexual erythrocytic stages) were assessed by ELISA in sera collected on the day of injection of PfSPZ Challenge and 28 days later. An individual was arbitrarily considered to have had development of antibodies to a specific antigen if the difference between
the OD 1.0 (serum dilution at which the optical density was 1.0) on Day 28 and the OD 1.0 before injection of PISPZ Challenge (net OD 1.0) was ≥50 and the ratio of OD 1.0 on Day 28 to the OD 1.0 before injection (OD 1.0 Ratio) was ≥2.5.

The results are summarized in Supplemental Table 2, Table 5, and Figure 1A–F. None of the volunteers developed antibodies to PfEBA-175, but antibodies were developed to PICSP, PiEXP1, and PiMSP1. The greatest percentage of responders was to PiEXP1 (68%), as was the highest net OD 1.0 among responders (261), whereas the OD 1.0 ratio was 2.6.

The highest OD 1.0 ratios were to PiMSP1. Only volunteers who developed *P. falciparum* parasitemia developed antibodies to PiMSP1 or PiEXP1, but one volunteer who did not develop parasitemia developed antibodies to PICSP, PiEXP1, and PiMSP1. The greatest percentage of responders was to PiEXP1 (68%), as was the highest net OD 1.0 among responders (261), whereas the OD 1.0 ratio was 2.6.

The results (see Supplemental Table 1 and Supplemental Figure 1A and B). Antibody results did not correlate with the magnitude of maximum concentrations (Tmax) associated with the Day 7 post-malaria episode (nominal 168 hours) sample; subject maximum concentrations (Cmax) at this time ranged from 144 to 628 ng/mL. The mean Cmax was 290 ng/mL with a coefficient of variation (CV) of 45%. The mean elimination half-life was 62.8 hours (2.6 days) with a CV of 19%.

Subject-level DCQ PK parameters are listed in Figure 2D. The value of λz could not be estimated in eight subjects due to insufficient samples above the LLQ. All subjects had a time of maximum concentration (Tmax) associated with the Day 7 post-malaria episode (nominal 168 hours) sample; subject maximum concentrations (Cmax) at this time ranged from 144 to 628 ng/mL. The mean Cmax was 290 ng/mL with a coefficient of variation (CV) of 45%. The mean elimination half-life was 62.8 hours (2.6 days) with a CV of 19%.

Subject-level DCQ PK parameters are listed in Figure 2D. The value of λz could not be estimated in eight subjects due to insufficient samples above the LLQ. All subjects had a time of maximum concentration (Tmax) associated with the Day 7 post-malaria episode (nominal 168 hours) sample; subject maximum concentrations (Cmax) at this time ranged from 144 to 628 ng/mL. The mean Cmax was 290 ng/mL with a coefficient of variation (CV) of 45%. The mean elimination half-life was 62.8 hours (2.6 days) with a CV of 19%.

Combined CQ and DCQ urine concentrations reveal that 14 (78%) of the 18 participants had data above the LLQ at the final collection time. One additional participant had a sample below the LLQ on Day 21 but above the LLQ on Day 28. The maximum-recorded concentration was 262 μg/mL on Day 2. The maximum concentration recorded after the last dose of drug was 52.8 μg/mL on Day 7 (data not shown).

**DISCUSSION**

ID administration of infectious PISPZ by needle and syringe was safe and conferred malaria to 100% of recipients in three of the six groups. The levels of reactogenicity and safety of the PISPZ product administered by ID inoculation by needle and syringe were similar, if not less than when *P. falciparum* malaria is conferred by infected mosquito bite. Previous to this study, investigators demonstrated 83% infectivity of 2,500; 10,000; or 25,000 PISPZ administered by ID inoculation in two aliquots of 50 μL.5,16 These results were validated in African volunteers.5,18 We sought to improve on the efficiency of PISPZ infectivity by analyzing the effect of aliquot, volume, and PISPZ quantity. Contemporaneously
with the conduct of this study, IM\textsuperscript{18} and IV\textsuperscript{19} inoculations were shown to be highly successful.

To mimic mosquito via ID injection, we chose to weight our trial design to smaller injectate reasoning that the sporozoites might be trapped in larger injectate volumes, thereby minimizing capillary penetration. Of the six groups tested (Groups A–F), three demonstrated 100% infectivity in the transmission of \textit{P. falciparum} malaria (Group A: 4/4 subjects (1 withdrawal), 1 × 10\textsuperscript{4} PfSPZ in 50 μL/2 doses; Group C: 5/5 subjects, 1 × 10\textsuperscript{4} PfSPZ in 10 μL/2 doses; and Group F: 5/5 subjects, 5 × 10\textsuperscript{4} PfSPZ in 10 μL/8 doses). We did not find a clear association with either aliquot volume or PfSPZ quantity, but this may be reflective of the limitations of the needle and syringe administration. The mosquito proboscis is able to probe in an extremely efficient manner, ensuring delivery of PfSPZ to capillaries and into the circulation.\textsuperscript{20} This might also explain why IV PfSPZ has been proven to be so successful.\textsuperscript{19}

Whether microinjection devices could improve on the efficiency of PfSPZ administration remains to be tested. The mechanics of PfSPZ administration are critically important for PfSPZ Challenge, but also apply to administration of the promising PfSPZ vaccine, which is composed of identical PfSPZ that have been radiation attenuated.\textsuperscript{15,21} The efficiency of PfSPZ to enter circulation may also influence the kinetics of malaria infection. The overall prepatent period by blood smear in this study was a mean of 13.5 days (range 12–16) and the shortest prepatent period was 12.7 days. This was more than the 10.9 days we have seen in CHMI administered by the bite of mosquitoes,\textsuperscript{10,11} but consistent with what has been noted in prior PfSPZ Challenge by the ID and IM routes. qPCR successfully detected parasitemia with a mean of 10.7 days after CHMI (range 8.4–11.9). This was

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{figure1.png}
\caption{Depicted are antibodies expressed as net optical density (OD) (A–C) and ratio OD (D–F) to \textit{Plasmodium falciparum} circumsporozoite protein (PICSP), \textit{P. falciparum} exported protein 1 (PIEXP1), and \textit{P. falciparum} merozoite surface protein 1 (PIMSPI) by enzyme-linked immunosorbent assay (ELISA) in sera collected 28 days after administration of \textit{P. falciparum} sporozoite (PfSPZ) Challenge and stratified by group (Group A [10,000 PfSPZ, 2 × 50 μL], B [10,000 PfSPZ, 8 × 50 μL], C [10,000 PfSPZ, 2 × 10 μL], D [10,000 PfSPZ, 8 × 10 μL], E [50,000 PfSPZ, 2 × 10 μL], and F [50,000 PfSPZ, 8 × 10 μL]). The dotted line represents the threshold end point titer ≥ 50, which is considered to be indicative of antibody production. The closed circles represent individuals who did not develop parasitemia. Note: Sera were missing from one aparasitemic volunteer in Group B.}
\end{figure}
longer than the 6.5 days seen in the mosquito bite studies.\textsuperscript{10,11} The growth rate in the blood appeared similar to traditional CHMI. Thus, this prolonged prepatent period almost certainly reflected the numbers of PfSPZ that successfully traveled from the skin to the liver, invaded hepatocytes, and fully developed to blood stage.

On examination of the individual groups, Group F was deemed to have the most parameters aligned with the traditional CHMI administered by the bite of mosquito (prepatent period = 12.7 days [range 12–14 days]). The group sample sizes were limited to five individuals, for practical reasons of malaria management, and capped at a total study size of 30 volunteers. Although this was not powered to achieve statistical significance, CHMI is a potent technique with a discrete outcome measure of “infected” or “not infected.” Sample sizes of five or six individuals are commonly used as controls in CHMI in which 100% infectivity would be expected. Hence, departure from this expected outcome would be a reliable study outcome. The clinical signs and symptoms associated with mosquito-transmitted malaria were also most similar in the volunteers who received 5 × 10\textsuperscript{4} PfSPZ. These symptoms were expected and transient in nature, resolving on malaria therapy. In addition, transient laboratory abnormalities associated with clinical malaria were noted, characterized by rises in AST, ALT, bilirubin, and creatinine and transient declines in hemoglobin and white blood cells in some subjects. These laboratory abnormalities were within the expected range of findings associated with mild \textit{P. falciparum} malaria and were evenly distributed across all groups. All abnormalities resolved without sequelae.

An isolated finding of a transient positive qPCR after the diagnostic study period is of questionable significance. First, qPCR was a research modality and not a widely accepted means of diagnosis at the time of this study. The presence of gametocytes might be expected after treatment at Day 28 post-CHMI (13 days following therapy) and could account for transient low-level qPCR positivity.\textsuperscript{22} Gametocytes being largely resistant to most anti-malarial treatment can persist within the circulation weeks after treatment.\textsuperscript{23} The qPCR detection self-resolved before administration of any anti-malarial product, and the malaria culture (the most sensitive detection method) remained negative at 4 weeks. Importantly, the subject remained asymptomatic and blood smear negative throughout follow-up evaluation.

The antibody findings are important in that they show the antibody profile 4 weeks after a single exposure to PfSPZ and ∼2 weeks after initiation of successful treatment of a single, low parasite density parasitemia. About 36% of subjects developed low levels of antibodies to the sporozoite and early liver stage antigen, PfCSP. Interestingly, the incidence rate of seroconversion and the magnitude of response were related to the dose. In those who received 1 × 10\textsuperscript{4} PfSPZ, 4/18 (22%)}
seroconverted and among those who received $5 \times 10^4$ PfSPZ, 6/10 (60%) ($P = 0.09$, Fisher’s exact test, 2 tailed). The magnitude of net OD 1.0 was ~10 times higher in the $5 \times 10^4$ PfSPZ groups (GM net OD 1.0 of 261 versus 24, $P = 0.003$, Mann–Whitney $U$ test). The responses to PfEXP1 and PfMSP1 were greater than to PICSP, and almost certainly reflect exposure to these antigens during the ~8 days from initial release of parasites from the liver (~Day 5.5) to initiation of treatment (Day 13.5), as the five individuals who did not develop parasitemia did not develop antibodies to these two antigens (Figure 1). The incidence rate of seroconversion to PfEXP1 (68%) was not significantly different from that to PfMSP1 (50%). However, the magnitude of net OD 1.0 was higher for PfEXP1 and the ratio of post- to pre-net OD 1.0 was higher for PfMSP1. It is unclear as to why antibodies did not develop to PfEBA-175. The IFA results were also consistent with ELISA results (see Supplemental Tables 1 and 2 and Supplemental Figure 1A and B).

CQ and DCQ levels (sera and urine) were calculated to determine effective dose levels and drug kinetics during the treatment phase of the study. Samples were collected at all six time points to ascertain a kinetic profile of drug detection after a single treatment regimen (1,500 mg CQ base/2,500 mg salt as malaria treatment over 48 hours). It appears, based on these data, that a single CQ dosing regimen results in detectable CQ and DCQ levels above the LLQ (51 and 43 ng/mL, respectively) out to Day 14 post-administration in all 18 volunteers tested; however, the assay was limited in quantification of levels below the LLQ, which was 10-fold greater than the minimal inhibitory concentration biologically required to inhibit parasite growth (5 ng/mL). These results may prove valuable in optimizing directly observed therapy in the PfSPZ-CVac model of injecting non-irradiated, fully infective PfSPZ serially under cover of anti-malarial prophylaxis as a means of achieving full protection against malaria.

In conclusion, ID administration of aseptic, purified, cryopreserved, infectious PfSPZ (PfSPZ Challenge) by needle and syringe was safe and transmitted malaria to 100% of human subjects in three of the six groups. About 100% infection with the shortest prepatent period was achieved in the group that received the highest dose ($5 \times 10^4$ PfSPZ) in the most inoculations ($N = 8$), suggesting that a further reduction in the prepatent period should come from increasing the numbers of PfSPZ and inoculations. Administering so many different inoculations by needle and syringe may prove cumbersome, so microneedle array injection is being considered. However, the report that IV or direct venous inoculation of far fewer PfSPZ achieves 100% infection with a prepatent period of 11.3 days $^{19}$ establishes a target level of infection with a target number of PfSPZ for those working to achieve similar results by ID injection, a result that may prove difficult to achieve.

Received May 8, 2015. Accepted for publication July 30, 2015.

Note: Supplemental tables and figure appear at www.atmhm.org.

Acknowledgments: We thank the volunteer population from Baltimore, MD who so graciously consented to participate in this trial. Lee F. Hall and Steven Rosenthal and Walter Jones of the Department of Microbiology and Infectious Diseases at the National Institute of Health offered invaluable support and advice, although program staff from the NIAID played no role in the collection, analysis or interpretation of data, writing the paper, or the decision to submit it for publication. Our special thanks go to Xiaolin Wang and Aly Kwon for coordination of the trial and for regulatory oversight, the entire Sanaria Manufacturing team for production of PfSPZ Challenge and to the Sanaria Quality, Regulatory, and Clinical teams for their support. We are grateful to Natasha KC for performing all ELISA assessments and Maria Orozco for IFA assessments. The EMMES Corporation provided database and statistical support. We thank Thomas L. Richie for manuscript review.

Clinical Trials Registry: This clinical trial has been registered on clinicaltrials.gov, registry number NCT01546389 (https://clinicaltrials.gov/ct2/show/NCT01546389).

Financial support: The development and manufacturing of PfSPZ Challenge was also supported by Small Business Innovation Research (SBIR) (grants R44AI058375-03, 04, 05, 05S1) from the National Institute of Allergy and Infectious Diseases at the National Institute of Health (NIAID/NIH) to SLH. The clinical trial was supported by federal funds from the NIAID/NIH, Department of HHS, under Vaccine Training Evaluation Unit Contract No. HHSN2722008000001C, to the University of Maryland, Baltimore, Center for Vaccine Development.

Disclosures: Sanaria Inc. manufactured PfSPZ Challenge, and Protein Potential LLC is affiliated with Sanaria. Thus, all authors associated with Sanaria or Protein Potential have potential conflicts of interest. There are no other conflicts of interest.

Authors’ addresses: Kirsten E. Lyke, Matthew B. Laurens, Kathy Strauss, Matthew Adams, and Robert Edelman, Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD, E-mails: klyke@medicine.umaryland.edu, mlaurens@medicine.umaryland.edu, kstrauss@medicine.umaryland.edu, madams@medicine.umaryland.edu, and redelman@medicine.umaryland.edu. Peter F. Billingsley, Eric James, Anita Manoj, Sumana Chakravarty, Adam Ruben, and Stephen L. Hoffman, Sanaria Inc., Rockville, MD, E-mails: pbillingsley@sanaria.com, ejames@sanaria.com, amanoj@sanaria.com, schakravarty@sanaria.com, aruben@sanaria.com, and shoffman@sanaria.com. Christopher V. Plowe, Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD, and Howard Hughes Medical Institute, University of Maryland School of Medicine, Baltimore, MD, E-mail: cplowe@medicine.umaryland.edu. Ming Lin Li, Protein Potential LLC, Rockville, MD, E-mail: mlil@proptop.com. Michael Green, Centers for Disease Control and Prevention, Atlanta, GA, E-mail: mdg4@cdc.gov. Tina J. Dube, The Emmes Corporation, Rockville, MD, E-mail: tdube@emmes.com. B. Kim Lee Sim, Sanaria Inc., Rockville, MD, and Protein Potential LLC, Rockville, MD, E-mail: ksim@sanaria.com.

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

REFERENCES

1. Stout JA, Slouoi M, Heppner DG, Momin P, Kester KE, Desmons P, Welde BT, Garcon N, Krzych U, Marchand M, RTS,S Malaria Vaccine Evaluation Group 1997. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. N Engl J Med 336: 86–91.
2. Gordon DM, McGovern TW, Krzych U, Cohen JC, Schneider I, LaChance R, Heppner DG, Yuan G, Hollingdale M, Slouoi M, 1995. Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine. J Infect Dis 171: 1576–1585.
3. Moorthy VS, Diggs C, Ferro S, Good MF, Herrera S, Hill AV, Imoukhuede EB, Kumar S, Loucq C, Marsh K, Ockenhouse CF, Richie TL, Sauerwein RW, 2009. Report of a consultation on the optimization of clinical challenge trials for evaluation of candidate blood stage malaria vaccines, 18–19 March 2009, Bethesda, MD, USA. Vaccine 27: 5719–5725.
4. Kester KE, McKinney DA, Tornepoth N, Ockenhouse CF, Heppner DG, Hall T, Krzych U, Delchambre M, Voss G,
Dowler MG, Palensky J, Wittes J, Cohen J, Ballou WR, 2001. Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria. J Infect Dis 183: 640–647.

5. Roestenberg M, Bijker EM, Sim BK, Billingsley PF, James ER, Bastiaens GJ, Teitzel GC, Scholzen A, Teelen K, Arens T, van der Ven AJ, Gunasekera A, Chakravarty S, Velmurugan S, Hermsen CC, Sauerwein RW, Hoffman SL, 2013. Controlled human malaria infections by intradermal injection of cryopreserved Plasmodium falciparum sporozoites. Am J Trop Med Hyg 88: 5–13.

6. Shekalaghe S, Rutaiwa M, Billingsley PF, Chemba M, Daubenberger CA, James ER, Mpina M, Ali JO, Schindler T, Huber E, Gunasekera A, Manoj A, Simon B, Saverwein E, Church LW, Hermsen CC, Sauerwein RW, PLOWE C, van der Ven AJ, Laurens MB, Adams M, Lyke KE, Laurens M, Adams M, Billingsley PF, Richman A, van de Ven AJ, Gunasekera A, Chakravarty S, Velmurugan S, Hermsen CC, Sauerwein RW, Hoffman SL, 2013. Controlled human malaria infections by intradermal injection of aseptically purified, cryopreserved Plasmodium falciparum sporozoites. Am J Trop Med Hyg 91: 471–480.

Gaziano TA, Young CR, Fitzmaurice G, Atwood S, Gaziano JM, 2008. Laboratory-based versus non-laboratory-based method for assessment of cardiovascular disease risk: the NHANES I Follow-up Study cohort. Lancer 371: 923–931.

8. Patchen LC, Mount DL, Schwartz IK, Churchill FC, 1983. Analysis of filter-paper-absorbed, finger-stick blood samples for chloroquine and its major metabolite using high-performance liquid chromatography with fluorescence detection. J Chromatogr A 278: 81–89.

Mount DL, Nahlen BL, Patchen LC, Churchill FC, 1989. Adaptations of the Saker-Solomons test: simple, reliable colorimetric field assays for chloroquine and its metabolites in urine. Bull World Health Organ 67: 295–300.

10. Lyke KE, Laurens M, Adams M, Billingsley PF, Richman A, Loyevsky M, Chakravarty S, PLOWE C, Sim BK, Edelman R, Hoffman SL, 2010. Plasmodium falciparum malaria challenge by the bite of aseptic Anopheles stephensi mosquitoes: results of a randomized infectivity trial. PLoS One 5: e13490.

11. Laurens MB, Billingsley P, Richman A, Eappen AG, Adams M, Li T, Chakravarty S, Gunasekera A, Jacob CG, Sim BK, Edelman R, PLOWE C, Hoffman SL, Lyke KE, 2013. Successful human infection with P. falciparum using three aseptic Anopheles stephensi mosquitoes: a new model for controlled human malaria infection. PLoS One 8: e68969.

12. Spring MD, Cummings JF, Ockenhouse CF, Dutta S, Reidel R, Angov E, Bergmann-Leitner E, Stewart VA, Birkett A, Plowe CV, Sim BK, Edelman R, PLOWE C, Hoffman SL, Lyke KE, 2013. Successful human infection with P. falciparum using three aseptic Anopheles stephensi mosquitoes: a new model for controlled human malaria infection. PLoS One 8: e68969.

13. McCutchan TF, de la Cruz VF, Lal AA, Gunderson JH, Elwood HJ, Sojín ML, 1988. Primary sequences of two small subunit ribosomal RNA genes from Plasmodium falciparum. Mol Biochem Parasitol 28: 63–68.

14. Gunderson JH, Sojín ML, Wollett G, Hollingdale M, de la Cruz VF, Waters AP, McCutchan TF, 1987. Structurally distinct, stage-specific ribosomes occur in Plasmodium. Science 238: 933–937.

15. Epstein JE, Tewari K, Lyke KE, Sim BK, Billingsley PF, Laurens MB, Gunasekera A, Chakravarty S, James ER, Sedegah M, Richman A, Velmurugan S, Reyes S, Li M, Tucker K, Ahumada A, Ruben AJ, Li T, Stafford R, Eappen AG, Tamminga C, Bennett JW, Ockenhouse CF, Murphy JR, Komisar J, Thomas N, Loyevsky M, Birkett A, PLOWE C, Loucq C, Edelman R, Richie TL, Seder RA, Hoffman SL, 2011. Live attenuated malaria vaccine designed to protect through hepatic CD8+ T cell immunity. Science 334: 425–480.

16. Bejon P, Andrews L, Andersen RF, Dunachie S, Webster D, Walther M, Gilbert SC, Peto T, Hill AV, 2005. Calculation of liver-to-blood inocula, parasite growth rates, and preerythrocytic vaccine efficacy, from serial quantitative polymerase chain reaction studies of volunteers challenged with malaria sporozoites. J Infect Dis 191: 619–626.

17. Roestenberg M, O’Hara GA, Duncan CJ, Epstein JE, Edwards NJ, Scholzen A, van der Ven AJ, Hermsen CC, Hill AV, Sauerwein RW, 2012. Comparison of clinical and parasitological data from controlled human malaria infection trials. PLoS One 7: e38434.

18. Sheehy SH, Spencer AJ, Douglas AD, Sim BK, Longley RJ, Edwards NJ, Poulton ID, Kimani D, Williams AR, Anagnostou NA, Roberts R, Kerridge S, Voysey M, James ER, Billingsley PF, Gunasekera A, Lawrie AM, Hoffman SL, Hill AV, 2013. Optimising controlled human malaria infection studies using cryopreserved parasites administered by needle and syringe. PLoS One 8: e56980.

19. Mordmuller B, Supan C, Sim BKL, Gómez-Pérez GP, Ospina Salazar CL, Held J, Bolte S, Mchumtoh J, Tshan S, Joanny F, Calle CL, Gunasekera A, James SL, Billingsley P, Richman A, Chakravarty S, Legarda A, Muñoz J, Antonijonam RD, Ballester MR, Hoffman SL, Alonso PL, Kahlcke F, 2013. Direct venous inoculation of Plasmodium falciparum sporozoites for controlled human malaria infection: a dose-finding trial in two centres. Malar J 12: 117.

20. Choumet V, Attout T, Chartier L, Khun H, Sautereau J, Robbe-Vincent A, Seidt L, Huerre M, Bain O, 2012. Visualizing non infectious and infectious Anopheles gambiae blood feedings in naive and saliva-immunized mice. PLoS One 7: e50464.

21. Seder RA, Chang L, Sharpe ME, Zephir KL, Sarwar UN, Gordon IJ, Holman L.A., James ER, Billingsley PF, Gunasekera A, Richman A, Chakravarty S, Manoj A, Velmurugan S, Li M, Ruben AJ, Li T, Eappen AG, Stafford RE, Plummer SH, Hendel CS, Novik L, Costner PJ, Mendoza FH, Saunders JC, Nason MC, Richardson JH, Murphy J, Davidson SA, Ritchie TL, Sedegah M, Sutamihardja A, Fahle GA, Lyke KE, Laurens MB, Roederer M, Tewari K, Epstein JE, Sim BK, Ledgerwood JE, Graham BS, Hoffman SL, 2013. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science 341: 1359–1365.

22. Robert V, Awo-Okon-Ambene HP, Le Hesran JY, Trape JF, 2000. Gametocytemia and infectivity to mosquitoes of patients with uncomplicated Plasmodium falciparum malaria attacks treated with chloroquine or sulfadoxine plus pyrimethamine. Am J Trop Med Hyg 62: 210–216.

23. White NJ, 2008. How antimalarial drug resistance affects post-treatment prophylaxis. Malar J 7: 9.